Tissue EV+biofluid EV biomarker research solution
Biofluids such as plasma/serum are easy to obtain and non-invasive, making exosomes derived from biofluids a very promising marker for disease diagnosis and treatment.
Quick Facts
- Advanced Exosome Technologies
- Services
- Biofluids such as plasma/serum are easy to obtain and non-invasive, making exosomes derived from biofluids a very promising marker for disease diagnosis and treatment. biofluid exosomes contain a large number of blood cell-derived exosomes, and various tissues and organs can release exosomes into biofluids, which are very mixed and greatly increase the difficulty of detecting disease-specific exosomes in biofluids. Tissue exosomes focus on exosomes derived from the lesion tissue. Combining tissue exosomes with plasma exosomes can screen specific exosome signals in biofluid exosomes that are more likely to come from the lesion tissue, improve the accuracy of potential marker discovery, and reduce the probability of false positive marker discovery.
Service Overview
Biofluids such as plasma/serum are easy to obtain and non-invasive, making exosomes derived from biofluids a very promising marker for disease diagnosis and treatment. biofluid exosomes contain a large number of blood cell-derived exosomes, and various tissues and organs can release exosomes into biofluids, which are very mixed and greatly increase the difficulty of detecting disease-specific exosomes in biofluids. Tissue exosomes focus on exosomes derived from the lesion tissue. Combining tissue exosomes with plasma exosomes can screen specific exosome signals in biofluid exosomes that are more likely to come from the lesion tissue, improve the accuracy of potential marker discovery, and reduce the probability of false positive marker discovery.
• Rich experience in biofluid exosomes. Relying on independent patented exosome isolation kit Exosupur ® and ultrasonic separation methods, 30+ kinds of biofluid exosome isolation experience, the number of samples reaches 30,000+, serving customers and publishing 100+ articles such as JEV
Relying on its own patented exosome isolation kit Exosupur ® and ultraionization and other methods, it has experience in isolating exosomes from 30+ biofluids, with a sample number of 30,000+, and has served customers and published 100+ articles such as JEV
• Rich experience in tissue exosomes. Possess patents related to tissue exosomes, 80+ experience in isolating tissue exosomes, and have published many articles of around 10 points for serving customers, such as Theranostics, J Am Chem Soc, Pharmacol Res, etc.
Possessing patents related to tissue exosomes, 80+ experience in isolating tissue exosomes, serving clients and publishing multiple articles of around 10 points, such as Theranostics, J Am Chem Soc, Pharmacol Res, etc.
FAQ
Q: IF tissue exosomes and biofluid exosomes are tested at the same time, but no intersection-differential exosome molecules are screened, what should be done?
What should we do IF we conduct tissue exosomes and biofluid exosomes at the same time, but no overlapping exosome molecules are screened?
A: This situation is relatively normal. After tissue exosomes leak into biofluids, they will be diluted or masked by a large number of signals. Being able to find exosome molecules that come from tissue exosomes and enter biofluids further illustrates the reliability of the marker molecules. IF such a situation occurs, it is recommended that: 1. You can try to lower the molecular screening threshold for different sample types and expand the scope of candidate molecules; 2. You can publish two articles separately, one focusing on the analysis of exosomes in the tissue microenvironment, and the other focusing on molecular screening of exosome markers in biofluids.
Q: When conducting tissue exosome and biofluid exosome screening marker studies at the same time, do the individuals enrolled need to be consistent?
When conducting tissue exosome and biofluid exosome screening marker studies at the same time, do the individuals enrolled need to be consistent?
Sample Submission Guidance
For details, please refer to the specific sample delivery suggestions page for each omics of tissue exosomes and each omics of biofluid exosomes.
Related Products
FAQ
- What service is Tissue EV+biofluid EV biomarker research solution?
- Tissue EV+biofluid EV biomarker research solution is an exosome technical service under the Advanced Exosome Technologies category. Biofluids such as plasma/serum are easy to obtain and non-invasive, making exosomes derived from biofluids a very promising marker for disease diagnosis and treatment.
- What research needs can Tissue EV+biofluid EV biomarker research solution support?
- Tissue EV+biofluid EV biomarker research solution is intended for research needs related to Advanced Exosome Technologies; sample type, testing targets, and analysis depth can be confirmed based on project goals.
- What does the Tissue EV+biofluid EV biomarker research solution workflow include?
- The current page describes modules such as Service Overview, FAQ, Sample Submission Guidance, and Related Products.
- What deliverables are available for Tissue EV+biofluid EV biomarker research solution?
- Deliverables usually include testing results, analysis data, figures, or project reports. The final format and depth should be confirmed according to the service plan, sample status, and project goals.
- How can customers discuss Tissue EV+biofluid EV biomarker research solution?
- Customers can contact Echo Biotech with sample type, research objective, expected testing scope, and timeline requirements to confirm a suitable Tissue EV+biofluid EV biomarker research solution service plan.